英文字典中文字典


英文字典中文字典51ZiDian.com



中文字典辞典   英文字典 a   b   c   d   e   f   g   h   i   j   k   l   m   n   o   p   q   r   s   t   u   v   w   x   y   z       







请输入英文单字,中文词皆可:


请选择你想看的字典辞典:
单词字典翻译
rimed查看 rimed 在百度字典中的解释百度英翻中〔查看〕
rimed查看 rimed 在Google字典中的解释Google英翻中〔查看〕
rimed查看 rimed 在Yahoo字典中的解释Yahoo英翻中〔查看〕





安装中文字典英文字典查询工具!


中文字典英文字典工具:
选择颜色:
输入中英文单字

































































英文字典中文字典相关资料:


  • Tevimbra: Uses, Dosage, Side Effects, Warnings - Drugs. com
    Tevimbra is used to treat adults with certain types of esophageal squamous cell carcinoma (ESCC), gastric adenocarcinoma, or gastroesophageal junction adenocarcinoma that has spread (metastasized) or cannot be surgically removed
  • ESCC and GC GEJC Treatment | TEVIMBRA® (tislelizumab-jsgr)
    TEVIMBRA is a prescription medicine used to treat adults with: cancer of the tube that connects your throat to your stomach (esophageal cancer) TEVIMBRA may be used in combination with chemotherapy that contains platinum as your first treatment when your esophageal cancer: is a type called squamous cell carcinoma, and cannot be removed with surgery or has spread to other parts of the body
  • TEVIMBRA® (tislelizumab-jsgr) for Esophageal Squamous Cell . . .
    Jaffer A Ajani, MD, reviews the available treatment options for esophageal cancer, including a unique compound that is designed to more effectively block the PD-1 receptor
  • TEVIMBRA Approved in U. S. for First-line Treatment of . . .
    TEVIMBRA is also approved in the U S as monotherapy for the treatment of adult patients with unresectable or metastatic esophageal squamous cell carcinoma after prior systemic chemotherapy that did not include a PD- (L)1 inhibitor and in combination with chemotherapy for the first-line treatment of adults with gastric and gastroesophageal
  • Drugs Approved for Esophageal Cancer - NCI
    This page lists cancer drugs approved by the Food and Drug Administration (FDA) for esophageal cancer The list includes generic names and brand names The drug names link to NCI's Cancer Drug Information summaries
  • Tevimbra: A New Treatment for Esophageal Squamous Cell Carcinoma
    TEVIMBRA is indicated for the treatment of adult patients with unresectable or metastatic esophageal squamous cell carcinoma after prior systemic chemotherapy that did not include a PD- (L)1 inhibitor Tevimbra was approved on March 13, 2024 What is the name of the drug and what does it do?
  • label - accessdata. fda. gov
    INDICATIONS AND USAGE 1 1 Esophageal Cancer First-Line Treatment of Esophageal Squamous Cell Carcinoma TEVIMBRA, in combination with platinum-containing chemotherapy, is indicated for the first-line treatment of adults with unresectable or metastatic esophageal squamous cell carcinoma (ESCC) whose tumors express PD-L1 (≥1)
  • Tislelizumab: Side Effects, Uses, Dosage, Interactions, Warnings
    Tislelizumab is a prescription medication indicated for: Esophageal Cancer In combination with platinum-containing chemotherapy as first-line treatment of adults with unresectable or metastatic esophageal squamous cell carcinoma (ESCC) whose tumors express programmed death- (Ligand) 1 [PD- (L)1] (greater than or equal to 1) As a single agent in adults with unresectable or metastatic ESCC
  • BeOne Medicines Tevimbra (Tislelizumab-jsgr) Monograph for . . .
    The treatment can be used in varying doses in two-, three-, or four-week intervals for adults as a first-line or single-agent treatment of unresectable or metastatic esophageal squamous cell carcinoma and in combination with platinum and fluoropyrimidine-based chemotherapy for gastric cancer Medication Overview Brand Name: Tevimbra
  • TEVIMBRA Approved in U. S. for First-line Treatment of . . .
    An estimated 957,000 new esophageal cancer cases are projected in 2040, an increase of nearly 60% from 2020, underscoring the need for additional effective treatments 1 Esophageal cancer is a rapidly fatal disease, and more than two-thirds of patients have advanced or metastatic disease at the time of diagnosis, with an expected five-year





中文字典-英文字典  2005-2009